{"id":172881,"date":"2025-12-03T04:04:04","date_gmt":"2025-12-03T09:04:04","guid":{"rendered":"https:\/\/old.alphastreet.com\/india\/?p=172881"},"modified":"2025-12-03T04:04:04","modified_gmt":"2025-12-03T09:04:04","slug":"akums-drugs-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/akums-drugs-q2-fy26-earnings-results\/","title":{"rendered":"Akums Drugs Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Akums Drugs &amp; Pharmaceuticals Ltd, established in 2004 as India&#8217;s leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26.<\/p>\n<h2>Financial Highlights:<\/h2>\n<ul>\n<li>Revenues declined 1.45% year-on-year to \u20b91,018 crore from \u20b91,033 crore, with CDMO up 0.7% to \u20b9804 crore but API\/international formulations down.<\/li>\n<li>Total expenses rose 2.61% to \u20b9984 crore from \u20b9959 crore.<\/li>\n<li>Consolidated net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/c642fd82-772b-4a9a-b46c-c1d3ef4fd909.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> fell 35.82% to \u20b943 crore from \u20b967 crore, with EBITDA at \u20b994 crore (9.3% margin).<\/li>\n<li>Earnings per share dropped 37.44% to \u20b92.59 from \u20b94.14.<\/li>\n<\/ul>\n<p>Challenges from API price weakness and flat volumes impacted performance despite domestic formulations growth of 5.3%. \u200b<\/p>\n<h2>Outlook:<\/h2>\n<p>Akums Drugs &amp; Pharmaceuticals Ltd focuses on branded exports (Dapagliflozin to Switzerland), EU-GMP expansion, and domestic growth to improve margins and shareholder value.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/alphastreet.com\/india\/symbol\/akums\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172882\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/AK.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akums Drugs &amp; Pharmaceuticals Ltd, established in 2004 as India&#8217;s leading pharmaceutical CDMO offering comprehensive product development and manufacturing services across formulations, reported lower profitability for Q2FY26. Financial Highlights: Revenues declined 1.45% year-on-year to \u20b91,018 crore from \u20b91,033 crore, with CDMO up 0.7% to \u20b9804 crore but API\/international formulations down. Total expenses rose 2.61% to [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172882,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-172881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":172881,"position":0},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":180863,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-akums-drugs-pharmaceuticals-reports-14-8-revenue-growth-in-q3-fy26-results\/","url_meta":{"origin":172881,"position":1},"title":"Earnings Summary &#8211; Akums Drugs &amp; Pharmaceuticals Reports 14.8% Revenue Growth in Q3 FY26 Results","author":"Staff Correspondent","date":"February 15, 2026","format":false,"excerpt":"Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS), a pharmaceutical contract development and manufacturing organization (CDMO) announced its third-quarter and nine-month financial results for fiscal year 2026 on February 13, 2026. On the day results were released, the stock closed at \u20b9484.95, representing a one-day gain of \u20b933.60 or 7.44%. Quarterly\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":168657,"url":"https:\/\/alphastreet.com\/india\/akums-drugs-12-rise-in-revenue\/","url_meta":{"origin":172881,"position":2},"title":"Akums Drugs &#038; Pharmaceuticals Ltd Q4FY25; 12% rise in Revenue","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. Financial Results: Akums Drugs & Pharmaceuticals Ltd reported Revenues for Q4FY25 of \u20b91,056.00 Crores up from \u20b9944.00 Crore year on year, a rise of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/U-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142550,"url":"https:\/\/alphastreet.com\/india\/earnings-aurobindo-pharma-ltd-nseauropharma-q3fy23-results-out-total-income-rise-7-yoy\/","url_meta":{"origin":172881,"position":3},"title":"Earnings | Aurobindo Pharma Ltd. (NSE:AUROPHARMA): Q3FY23 Results Out; Total Income rise 7% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Aurobindo Pharma Ltd. (NSE:AUROPHARMA) is a global pharmaceutical company headquartered in India. The company produces and sells a wide range of generic pharmaceutical products and active pharmaceutical ingredients (APIs) in over 150 countries. Aurobindo Pharma's portfolio includes antibiotics, anti-retrovirals, anti-inflammatory drugs, cardiovascular drugs, and more. The company operates manufacturing facilities\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":177762,"url":"https:\/\/alphastreet.com\/india\/innova-captab-limited-performance-market-environment-and-competitive-position\/","url_meta":{"origin":172881,"position":4},"title":"Innova Captab Limited Performance, Market Environment, and Competitive Position","author":"Staff Correspondent","date":"January 26, 2026","format":false,"excerpt":"Innova Captab Limited (NSE: INNOVACAP) has emerged as a noteworthy player in India's pharmaceutical landscape, combining contract development and manufacturing (CDMO) services with a branded generics business. In recent quarters, the company has delivered strong top-line growth coupled with improving profitability, reflecting both operational execution and expanding market reach. In\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/11\/tiny-pharmacist-with-pills-vitamins-flat-vector-illustration-doctors-writing-prescriptions-antibiotics-working-together-helping-patients-cure-pharmacy-business-drugstore-concept_74855-23225.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":169505,"url":"https:\/\/alphastreet.com\/india\/laurus-labs-ltd-q1-fy26-earnings-results-a-whopping-1146-rise-in-profits\/","url_meta":{"origin":172881,"position":5},"title":"Laurus Labs Ltd Q1 FY26 Earnings Results &#8211; A whopping 1146% rise in Profits","author":"Chirag Gupta","date":"July 29, 2025","format":false,"excerpt":"Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/5-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172881"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172881\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}